LAUSR

Background Since older age is a strong predictor of not only bleeding but also of ischemic events, understanding the risk:benefit profile of bivalirudin in the elderly undergoing primary percutaneous coronary intervention (pPCI) for ST‐segment elevation (STEMI) is important. For this, we aim to compare elderly with young patients, who all underwent pPCI for STEMI and randomly received either bivalirudin or heparin. Methods We performed a patient‐level pooled analysis (n = 5800) of two large randomized trials. A total of 2149 (37.1%) elderly patients (>65 years of age) with STEMI were enrolled and randomly assigned to either bivalirudin or heparin with or without a GPI (control group) before pPCI. Clinical outcomes at 30 days were analyzed. Results In elderly patients, bivalirudin significantly reduced non‐CABG major bleeding (7.1% vs 10.4%; P < .01), subacute ST (0.4% vs 1.5%; P < .01), and net adverse clinical events (NACE; composite of all‐cause mortality, reinfarction, IDR, stroke or protocol‐defined non‐CABG major bleeding [13.7% vs 17.2%; P = .03]) with comparable rates of stroke, MI, acute ST, or all‐cause death, when compared with heparin with or without GPI. Conclusions In a large group of elderly patients enrolled in the EUROMAX and HORIZONS‐AMI trials, bivalirudin was associated with lower 30‐day rates of non‐CABG major bleeding, subacute ST and NACE, with similar 30‐day rates of acute ST and mortality.